Urine test for glycated CD59 to detect pregnancy-related high blood sugar
Urine levels of Glycated CD59 for screening and diagnosis of pregnancy-induced glucose intolerance
A urine-based test that looks for a modified protein called glycated CD59 to find pregnancy-related high blood sugar in pregnant people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11286802 on NIH RePORTER |
What this research studies
This research looks at levels of a modified protein called glycated CD59 in urine to see if it can signal pregnancy-related high blood sugar or gestational diabetes. Researchers will compare urine GCD59 results with standard oral glucose tolerance tests and other clinical measures in pregnant people and in groups with high blood sugar. The team has prior experience measuring GCD59 in blood in thousands of people and will adapt and validate a urine assay across different hyperglycemic conditions. If accurate, the urine test could be easier, faster, and less unpleasant than current screening methods.
Who could benefit from this research
Good fit: Pregnant people being screened for gestational diabetes or those with risk factors for pregnancy-induced glucose intolerance (for example high BMI, prior gestational diabetes, or family history) would be ideal candidates.
Not a fit: People who are not pregnant or who require detailed diabetes management beyond initial screening may not benefit from this pregnancy-focused urine screening test.
Why it matters
Potential benefit: Could provide a simple, quicker, and less unpleasant urine screening test for gestational diabetes to help detect and treat pregnancy-related high blood sugar earlier.
How similar studies have performed: Earlier published work has measured GCD59 in blood in large groups (≈4,000 subjects) with promising results, but a validated urine-based screen for gestational diabetes remains novel.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Halperin, Jose a — Brigham and Women's Hospital
- Study coordinator: Halperin, Jose a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.